retatrutide biotech peptides 20mg | Triple GIP/GLP-1/Glucagon Research Resource GLP-3 R 30mg - Apollo

References Thorner MO

Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties

What are the most serious side effects that I or a caregiver should monitor for when taking Foundayo

Theres strong mechanistic plausibility, he said

This is a significant difference, and it was not observed in the Phase 2 trial making it a genuinely new finding